---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-029108"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:14:52.672934+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology shareholders approve increase in shares under 2021 equity plan to 8.15M

## Summary
- All seven director nominees elected: For votes ranged 15.2M–15.5M; no director received >601K abstentions.
- Ratification of BDO USA as auditor for FY2024 approved: 27.1M For, 0.26M Against, 0.33M Abstain.
- Amendment to 2021 Equity Incentive Plan increasing authorized shares to 8,150,000 approved: 13.1M For, 2.4M Against, 0.35M Abstain.
- Advisory vote on executive compensation passed: 13.3M For, 2.1M Against, 0.41M Abstain.
- All proposals passed; broker non-votes noted for director election, equity plan, and say-on-pay.

## SEC filing metadata
- accession: 0001628280-24-029108
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828024029108/0001628280-24-029108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828024029108/crdf-20240620.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-029108
- JSON: https://secwatch.observer/filing/0001628280-24-029108.json
- Plain text: https://secwatch.observer/filing/0001628280-24-029108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.